{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:03:04Z","timestamp":1782363784849,"version":"3.54.5"},"reference-count":21,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1620\/tjem.239.89","type":"journal-article","created":{"date-parts":[[2016,5,22]],"date-time":"2016-05-22T11:11:12Z","timestamp":1463915472000},"page":"89-94","source":"Crossref","is-referenced-by-count":14,"title":["Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes"],"prefix":"10.1620","volume":"239","author":[{"given":"Takaaki","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ueba","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Shinoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daita","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonobu","family":"Hatoko","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Yonemitsu","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Osaka Red Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., Folli, F., Defronzo, R.A. &amp; Tripathy, D. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. <i>Diabetes Care<\/i>, 32, 1542-1546.","DOI":"10.2337\/dc09-0684"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chen, C., Cheung, B.M., Tso, A.W., Wang, Y., Law, L.S., Ong, K.L., Wat, N.M., Xu, A. &amp; Lam, K.S. (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. <i>Diabetes Care<\/i>, 34, 2113-2115.","DOI":"10.2337\/dc11-0294"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Ciregia, F., Giusti, L., Ronci, M., Bugliani, M., Piga, I., Pieroni, L., Rossi, C., Marchetti, P., Urbani, A. &amp; Lucacchini, A. (2015) Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study. <i>Mol. Biosyst.<\/i>, 11, 1696-1707.","DOI":"10.1039\/C5MB00022J"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Fan, R., Li, X., Gu, X., Chan, J.C. &amp; Xu, G. (2010) Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. <i>Diabetes Obes. Metab.<\/i>, 12, 815-824.","DOI":"10.1111\/j.1463-1326.2010.01238.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Fujita, Y., Ito, M., Kojima, T., Yatsuga, S., Koga, Y. &amp; Tanaka, M. (2015) GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. <i>Mitochondrion<\/i>, 20, 34-42.","DOI":"10.1016\/j.mito.2014.10.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Iglesias, P., Selgas, R., Romero, S. &amp; D\u00edez, J.J. (2012) Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. <i>Eur. J. Endocrinol.<\/i>, 167, 301-309.","DOI":"10.1530\/EJE-12-0357"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Koene, S., de Laat, P., van Tienoven, D.H., Vriens, D., Brandt, A.M., Sweep, F.C., Rodenburg, R.J., Donders, A.R., Janssen, M.C. &amp; Smeitink J.A. (2014) Serum FGF21 levels in adult m.3243A&gt;G carriers: clinical implications. <i>Neurology<\/i>, 83, 125-133.","DOI":"10.1212\/WNL.0000000000000578"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Kurosu, H., Choi, M., Ogawa, Y., Dickson, A.S., Goetz, R., Eliseenkova, A.V., Mohammadi, M., Rosenblatt, K.P., Kliewer, S.A. &amp; Kuro-o, M. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. <i>J. Biol. Chem.<\/i>, 282, 26687-26695.","DOI":"10.1074\/jbc.M704165200"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Liang, C., Ahmad, K. &amp; Sue, C.M. (2014) The broadening spectrum of mitochondrial disease: shifts in the diagnostic paradigm. <i>Biochim. Biophys. Acta<\/i>, 1840, 1360-1367.","DOI":"10.1016\/j.bbagen.2013.10.040"},{"key":"10","doi-asserted-by":"crossref","unstructured":"McDonnell, M.T., Schaefer, A.M., Blakely, E.L., McFarland, R., Chinnery, P.F., Turnbull, D.M. &amp; Taylor, R.W. (2004) Noninvasive diagnosis of the 3243A &gt; G mitochondrial DNA mutation using urinary epithelial cells. <i>Eur. J. Hum. Genet.<\/i>, 12, 778-781.","DOI":"10.1038\/sj.ejhg.5201216"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Mukai, E., Fujimoto, S., Sato, H., Oneyama, C., Kominato, R., Sato, Y., Sasaki, M., Nishi, Y., Okada, M. &amp; Inagaki, N. (2011) Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. <i>Diabetes<\/i>, 60, 218-226.","DOI":"10.2337\/db10-0021"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Murakami, T., Shinoto, Y., Yonemitsu, S., Muro, S., Oki, S., Koga, Y., Goto, Y. &amp; Kaneda, D. (2016) Early onset of diabetes mellitus accelerates cognitive decline in Japanese patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. <i>Tohoku J. Exp. Med.<\/i>, 238, 311-316.","DOI":"10.1620\/tjem.238.311"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Ogata, M., Iwasaki, N., Ide, R., Takizawa, M. &amp; Uchigata, Y. (2014) GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic <i>\u03b2<\/i> cells. <i>Biochem. Biophys. Res. Commun.<\/i>, 447, 133-138.","DOI":"10.1016\/j.bbrc.2014.03.143"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Samson, S.L., Sathyanarayana, P., Jogi, M., Gonzalez, E.V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L. &amp; Bajaj, M. (2011) Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. <i>Diabetologia<\/i>, 54, 3093-3100.","DOI":"10.1007\/s00125-011-2317-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Schaefer, A.M., Phoenix, C., Elson, J.L., McFarland, R., Chinnery, P.F. &amp; Turnbull, D.M. (2006) Mitochondrial disease in adults: a scale to monitor progression and treatment. <i>Neurology<\/i>, 66, 1932-1934.","DOI":"10.1212\/01.wnl.0000219759.72195.41"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L. &amp; Zhan, S. (2012) Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. <i>Exp. Diabetes Res.<\/i>, 2012, 230624.","DOI":"10.1155\/2012\/230624"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Suzuki, S., Oka, Y., Kadowaki, T., Kanatsuka, A., Kuzuya, T., Kobayashi, M., Sanke, T., Seino, Y., Nanjo, K.; Research Committee or Specific Types of Diabetes Mellitus with Gene Mutations of the Japan Diabetes Society (2003) Clinical features of diabetes mellitus with the mitochondrial DNA 3243 (A-G) mutation in Japanese: maternal inheritance and mitochondria-related complications. <i>Diabetes Res. Clin. Pract.<\/i>, 59, 207-217.","DOI":"10.1016\/S0168-8227(02)00246-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Xu, A., Law, L.S., Chen, C., Li, H., Li, X., Yang, L., Liu, S., Zhou, Z. &amp; Lam, K.S. (2012) Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. <i>J. Clin. Endocrinol. Metab.<\/i>, 97, E54-58.","DOI":"10.1210\/jc.2011-1930"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Yang, M., Dong, J., Liu, H., Li, L. &amp; Yang, G. (2011) Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. <i>PLoS One<\/i>, 6, e26359.","DOI":"10.1371\/journal.pone.0026359"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Yatsuga, S., Fujita, Y., Ishii, A., Fukumoto, Y., Arahata, H., Kakuma, T., Kojima, T., Ito, M., Tanaka, M., Saiki, R. &amp; Koga, Y. (2015) Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. <i>Ann. Neurol.<\/i>, 78, 814-823.","DOI":"10.1002\/ana.24506"},{"key":"21","unstructured":"Yatsuga, S., Povalko, N., Nishioka, J., Katayama, K., Kakimoto, N., Matsuishi, T., Kakuma, T., Koga, Y. &amp; Taro Matsuoka for MELAS Study Group in Japan. (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. <i>Biochim. Biophys. Acta<\/i>, 1820, 619-624."}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/239\/2\/239_89\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:26:11Z","timestamp":1498314371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/239\/2\/239_89\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.239.89","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}